Company
Illumina, Inc.
Headquarters: San Diego, CA, United States
Founded: 1998
Employees: 9,800
CEO: Mr. Francis A. deSouza
Market Cap
$16.77 Billion
USD as of July 1, 2024
Illumina, Inc. Categories
United States Healthcare Diagnostics & ResearchUnited States Healthcare United States Diagnostics & Research
Company Description
Illumina, Inc. is a biotechnology company specialized in DNA sequencing. It develops, manufactures, and markets genetic and biological analysis systems dedicated to the markets of gene sequencing, genotyping and gene expression, and proteomics. Thanks to its products, Illumina has been able to dramatically reduce the cost of human genome sequencing.
Top Competitors by Market Capitalization
Industry: Diagnostics & Research
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $204.45 B |
| Danaher | $177.21 B |
| Siemens Healthineers AG | $63.84 B |
| DexCom, Inc. | $45.21 B |
| Lonza Group Ltd | $39.85 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Illumina, Inc. has the following listings and related stock indices.
Stock: NASDAQ: ILMN wb_incandescent
Stock: BMV: ILMN wb_incandescent
Stock: Bovespa: I1LM34 wb_incandescent
Stock: FSX: ILU wb_incandescent
Product & Services
NovaSeq 600HiSeq X, HiSeq 400MiSeq, MiSeqDx, MiniSeq, iSeq 10NextSeq 55NextSeq 550Dx, iScan
Key People
Founder(s): David Walt Larry Bock John Stuelpnagel Anthony Czarnik Mark Chee
Francis de Souza (President & CEO) John W. Thompson (Board Chair) Sam Samad (CFO)
Financials
Revenue: US$1.093 Billion (Fiscal Year Ended January 3, 2021)
Operating income: US$0.580 Billion (Fiscal Year Ended January 3, 2021)
Net income: US$0.656 Billion (Fiscal Year Ended January 3, 2021)
Total assets: US$7.585 Billion (Fiscal Year Ended January 3, 2021)
Total equity: US$4.694 Billion (Fiscal Year Ended January 3, 2021)